K2bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

K2bio is a preclinical CRO and lab infrastructure provider headquartered in Houston, Texas, with a secondary presence in San Diego. Founded in 2018, the company has pivoted from its original focus on antibody-based biologics and drug delivery to a service-based model centered on its AAALAC-accredited vivarium and flexible lab incubator space. It offers integrated solutions for in vivo pharmacology, lab operations, and scientific support, primarily serving biotech and pharmaceutical clients in the Houston biotech hub. The company is privately held and appears to be in an early revenue-generating stage from its service contracts.

AntibodiesBiologicsDrug Delivery

Technology Platform

Integrated preclinical CRO services platform featuring an AAALAC-accredited vivarium, flexible lab incubator space, and expert-led scientific support for in vivo and in vitro research.

Opportunities

Capitalizing on Houston's development as a biotech hub by being the primary provider of contract vivarium and flexible lab space.

The growing trend of outsourcing preclinical R&D by virtual and small biotech companies creates sustained demand for its integrated CRO and infrastructure model.

Risk Factors

Demand is contingent on the growth of the local biotech ecosystem, facing competition from large global CROs.

High fixed costs of maintaining vivarium and lab facilities create financial vulnerability if utilization rates are low.

Competitive Landscape

Competes with large, global preclinical CROs (e.g., Charles River, Labcorp) and niche regional service providers. Its differentiation lies in combining AAALAC-accredited in vivo services with physical lab incubator space, targeting the specific need for infrastructure in emerging biotech hubs like Houston.

More companies in Biologics / Biosimilars →More companies in United States →